Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
Chehrazi-Raffle A, Meza L, Alcantara M, Dizman N, Bergerot P, Salgia N, Hsu J, Ruel N, Salgia S, Malhotra J, Karczewska E, Kortylewski M, Pal S. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. Journal For ImmunoTherapy Of Cancer 2021, 9: e002009. PMID: 33688021, PMCID: PMC7944971, DOI: 10.1136/jitc-2020-002009.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor tyrosine kinase inhibitorMetastatic renal cell carcinomaRenal cell carcinomaImmune checkpoint inhibitorsColony-stimulating factorClinical benefitPlasma cytokinesSystemic therapyCell carcinomaInterleukin-6Prospective correlative studyLines of therapyLow pretreatment levelsGranulocyte colony-stimulating factorGranulocyte-macrophage colony-stimulating factorRCC histologic subtypesMacrophage colony-stimulating factorICI armsICI therapyStable diseaseCheckpoint inhibitorsClinical responsePartial responseComplete responseImmunologic profileDistinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC).
Chehrazi-Raffle A, Meza L, Alcantara M, Salgia N, Dizman N, Bergerot P, Hsu J, Kortylewski M, Pal S. Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 352-352. DOI: 10.1200/jco.2021.39.6_suppl.352.Peer-Reviewed Original ResearchVascular endothelial growth factor tyrosine kinase inhibitorMetastatic renal cell carcinomaImmune checkpoint inhibitorsPlasma cytokinesClinical benefitCommon immune checkpoint inhibitorsICI combination therapyLow pretreatment levelsRenal cell carcinomaEligible patientsICI armsStable diseaseCheckpoint inhibitorsImmunologic profilePartial responseSystemic therapyComplete responseProspective studyIL-1raCell carcinomaCombination therapyIL-6Pretreatment levelsDistinct cytokinesG-CSF